论文部分内容阅读
应用RT PCR方法检测 3例正常卵巢、6例良性卵巢肿瘤和 16例恶性卵巢肿瘤组织中TNF家族新成员TRAIL的受体DR5 ,DcR1和DcR2表达。结果显示 :正常人外周血淋巴细胞及 3例正常卵巢组织中TRAIL受体均为阳性表达。良性卵巢肿瘤中DR5阳性表达率为 83.3% (5 /6 ) ,DcR1为 83.3% (5 /6 ) ,DcR2为 10 0 % (6 /6 )。恶性卵巢肿瘤中DR5阳性表达率为 6 8.8% (11/16 ) ,DcR1为 6 8.8% (11/16 ) ,DcR2为 0 % (0 /16 )。提示不同TRAIL受体特别是DcR2表达可能参与了卵巢肿瘤发生过程中细胞凋亡的调控
The expression of TRAIL receptor DR5, DcR1 and DcR2 in 3 normal ovaries, 6 benign ovarian tumors and 16 malignant ovarian tumors were detected by RT-PCR. The results showed that TRAIL receptors in normal human peripheral blood lymphocytes and in 3 normal ovarian tissues were all positive. The positive expression rates of DR5 in benign ovarian tumors were 83.3% (5/6), 83.3% (5/6) in DcR1, and 10% (6/6) in DcR2. The positive expression rates of DR5 in malignant ovarian tumors were 6 8.8% (11/16), DcR1 6 8.8% (11/16) and DcR2 0% (0/16). Suggesting that different TRAIL receptors, especially DcR2, may be involved in the regulation of apoptosis during ovarian tumorigenesis